Pacira BioSciences, Inc. PCRX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s cash & equivalents?
- Pacira BioSciences, Inc. (PCRX) reported cash & equivalents of $144.31M in Q1 2026.
- How has Pacira BioSciences, Inc.'s cash & equivalents changed year-over-year?
- Pacira BioSciences, Inc.'s cash & equivalents decreased by 49.1% year-over-year, from $283.61M to $144.31M.
- What is the long-term trend for Pacira BioSciences, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s cash & equivalents has grown at a 9.7% compound annual growth rate (CAGR), from $99.96M to $158.55M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.